Sun Pharma Q2FY26 net profit rises 2.5% to Rs 3,118 crore

Sun Pharmaceutical Industries officially announced here on Wednesday that it has reported a consolidated net profit of Rs 3,117.95 crore in the second quarter of FY26, registering a growth of 2.55% from Rs 3,040.16 crore in the year-ago period.

According to an official statement, the company’s total revenue from operations in Q2FY26 increased by almost 9% to Rs 14,478.31 crore from Rs 13,291.39 crore, on an year-on-year (YoY) basis.

Advertisement

The company reported an EBITDA of Rs 4,527.1 crore during the September quarter, recording a 14.9% YoY growth, with an EBITDA margin of 31.3%.

Sun Pharmaceutical Industries Managing Director Kirti Ganorkar said, “India, emerging markets and the rest of the world led our growth for the period. US sales of innovative medicines surpassed generics for the first time during the quarter”.

During the quarter, four Abbreviated New Drug Applications (ANDAs) were filed, while approval was received for 5 ANDAs. Sun’s portfolio includes 57 approved NDAs while 14 NDAs await US FDA approval. One NDA was filed during the quarter, according to the company’s official statement.

Formulation sales in India were at Rs 4,734.8 crore, registering a growth of 11%. India Formulation sales accounted for 32.9% of total consolidated sales for the quarter. The company launched 9 new products during the quarter and 15 products to date.

Formulation sales in Rest of World (RoW) markets were US$ 234 million for Q2FY26, were up by 17.7% and accounted for 14.2% of total consolidated sales for the quarter. For the first half, sales were US$ 453 million, up by 16.6% over the same period last year.

Emerging Markets formulations sales increased by 10.9% to $325 million for Q2FY26 and accounted for 19.7% of total consolidated sales. Formulation sales in Rest of World (RoW) markets were $234 million during the quarter, up by 17.7% and accounted for 14.2% of total consolidated sales for the quarter.

Global Innovative Medicines sales were US$ 333 million for Q2FY26, up 16.4% over Q2 last year and accounted for 20.2% of total consolidated sales for the quarter. For the first half, sales were US$ 644 million, up by 16.6% over the same period last year. During the quarter, Leqselvi was launched in the US for the treatment of severe alopecia areata.

For Q2FY26, external sales of Active Pharmaceutical Ingredients (APIs) were Rs 4,299 million, down by 19.5%. For the first half, API sales were Rs 9,702 million, a decline of 5.7% over the same period last year.